Sun Pharma Share Price in Focus as Board Approves ₹10,000 Crore NCD Issuance

Sun Pharmaceutical Industries Limited held a board meeting on October 12, 2026, where key decisions were made regarding the issuance of non-convertible debentures (NCDs) and the resignation of a board member. The meeting commenced at 5:00 P.M. and concluded at 5:50 P.M. IST, as per the exchange filings. 

Issuance of Non-Convertible Debentures 

The board approved the issuance of listed, rated, unsecured, redeemable non-convertible debentures (NCDs) on a private placement basis. The total amount for this issuance will not exceed ₹10,000 crore.  

This issuance may occur in one or more tranches and/or series. The Finance Committee has been authorised to determine and approve the specific terms and conditions for each tranche, including issuance, allocation, and allotment, within the framework set by the board. 

Resignation of Mr. Gautam Doshi 

Mr. Gautam Doshi, a Non-Executive, Independent Director, resigned from his position effective October 12, 2026, due to personal reasons.  

He confirmed that there are no material reasons for his resignation other than those stated in his resignation letter. Consequently, he has also ceased to hold positions on the committees of the board of directors of the company. 

Read More: Canara Robeco Asset Management Share Price in Focus After Q2 FY27 Earnings Results: Total Income Up 18.6% YoY! 

Sun Pharmaceutical Industries Share Price Performance 

As of October 13, 2026, at 3:24 PM, Sun Pharmaceutical Industries share price on NSE was trading at ₹1,768.40, up by 0.48% from the previous closing price. 

Conclusion 

Sun Pharmaceutical Industries' board approved the issuance of NCDs worth up to ₹10,000 crore and noted the resignation of Independent Director Gautam Doshi, who cited personal reasons for his departure. The board expressed appreciation for his contributions. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.